TWTR Twitter Inc.

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Twitter, Inc. Investors and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Twitter, Inc. (“Twitter” or the “Company”) (NYSE: TWTR) securities between February 6, 2015 and July 28, 2015, inclusive (the “Class Period”). Twitter investors have until November 15, 2016 to file a lead plaintiff motion.

Investors suffering losses on their Twitter investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to [email protected].

According to the Complaint filed in this lawsuit, throughout the Class Period defendants issued false and misleading statements, including: (a) that by early 2015, daily active users (“DAUs”) had replaced the timeline views metric as the primary user engagement metric tracked internally by Twitter management; (b) that the trend in user engagement growth was flat or declining; (c) that new product initiatives were not having a meaningful impact on Monthly Active Users (“MAUs”) or user engagement; (d) that Twitter’s stated “acceleration [in MAU growth]” was the result of low-quality MAU growth, and (e) that defendants lacked a basis for their previously issued projections of approximately 20% MAU growth and 550 million MAUs in the immediate term.

On April 28, 2015, Twitter issued its first quarter 2015 financial results and released its forecast for the second quarter of 2015, anticipating second quarter revenue of approximately $470 million to $485 million. Additionally, Twitter lowered its full year 2015 revenue guidance to between $2.17 billion and $2.27 billion. On this news, Twitter stock fell over 18% to close at just $42.27 per share on April 28, 2015.

Then, on July 28, 2015, post-market, Twitter issued a press release disclosing its second quarter 2015 financial results and announced its outlook for the third quarter of 2015, anticipating third quarter revenue of $545 million to $560 million. Twitter also provided its financial forecast for the full year of 2015, predicting revenue in the range of $2.20 billion to $2.27 billion. On this news, Twitter stock fell over 14% to close at $31.24 per share on July 29, 2015, thereby injuring investors.

If you purchased shares of Twitter during the Class Period you may move the Court no later than November 15, 2016 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
10/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Twitter Inc.

Wedbush Research
  • Wedbush Research
2454 MEDIATEK CORPORATION
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch